Abstract
In the light of increasing knowledge on the regulation of the efferent and afferent branches of antitumor immunity, on tumor-induced imbalances of immune response and on tumor escape mechanisms, it seem important to review the information available on the immunomodulating effects of anticancer drugs and their possible exploitation in cancer therapeutics. The immunomodulation induced by several antitumor antibiotics is considered with particular emphasis on the effects of Doxorubicin and their therapeutic exploitation. The immunomodulating effects of anticancer drugs considered include those of cyclophosphamide and other alkylating agents, of 6-mercaptopurine and other antimetabolities, of Vinca alkaloida, Taxanes, Thalidomide, Gleevec and Difluoromethyl ornithine. The positive effects on tumor immunity are discussed with reference to their potential exploitation in the therapeutics. The effects of certain anticancer drugs on tumor antigen expression are also discussed as a mechanism by which these agents increase tumor immunogenicity with consequent advantages for therapeutic exploitation and vaccine effectiveness. The need for increased molecular and clinical studies of anticancer drugs-induced immunomodulation is emphasized.
Keywords: Cyclophosphamide, Vinca Alkaloids, Adriamycin, cell antitumor effects, immunosuppression, Difluoromethyl Ornithine
Current Cancer Therapy Reviews
Title: Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Volume: 3 Issue: 3
Author(s): Enrico Mihich
Affiliation:
Keywords: Cyclophosphamide, Vinca Alkaloids, Adriamycin, cell antitumor effects, immunosuppression, Difluoromethyl Ornithine
Abstract: In the light of increasing knowledge on the regulation of the efferent and afferent branches of antitumor immunity, on tumor-induced imbalances of immune response and on tumor escape mechanisms, it seem important to review the information available on the immunomodulating effects of anticancer drugs and their possible exploitation in cancer therapeutics. The immunomodulation induced by several antitumor antibiotics is considered with particular emphasis on the effects of Doxorubicin and their therapeutic exploitation. The immunomodulating effects of anticancer drugs considered include those of cyclophosphamide and other alkylating agents, of 6-mercaptopurine and other antimetabolities, of Vinca alkaloida, Taxanes, Thalidomide, Gleevec and Difluoromethyl ornithine. The positive effects on tumor immunity are discussed with reference to their potential exploitation in the therapeutics. The effects of certain anticancer drugs on tumor antigen expression are also discussed as a mechanism by which these agents increase tumor immunogenicity with consequent advantages for therapeutic exploitation and vaccine effectiveness. The need for increased molecular and clinical studies of anticancer drugs-induced immunomodulation is emphasized.
Export Options
About this article
Cite this article as:
Enrico Mihich , Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics, Current Cancer Therapy Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339407781368350
DOI https://dx.doi.org/10.2174/157339407781368350 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pioglitazone, Bladder Cancer, and the Presumption of Innocence
Current Drug Safety P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia
Current Pharmacogenomics Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Immunotherapy in Bladder Cancer
Current Molecular Pharmacology Resveratrol and Its Analogues: Promising Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention
Current Drug Targets An Up-date of Olive Oil Phenols in Inflammation and Cancer: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Synthesis and Anti-cancer Activities of Apigenin Derivatives
Medicinal Chemistry Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy G-Protein Coupled Receptors (GPCRs): A Comprehensive Computational Perspective
Combinatorial Chemistry & High Throughput Screening Pluronic-Based Core/Shell Nanoparticles for Drug Delivery and Diagnosis
Current Medicinal Chemistry RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets A Comprehensive Review of Poorly Differentiated Neuroendocrine Carcinomas (pdNECs): a Niche to Find Novel Opportunities
Current Pharmaceutical Design Perinatal Management of Fetal Tumors
Current Pediatric Reviews Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Current Drug Metabolism Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry HSP60 as a Drug Target
Current Pharmaceutical Design Exposing “Bright” Metals: Promising Advances in Photoactivated Anticancer Transition Metal Complexes
Current Medicinal Chemistry